Skip to main content

Table 3 The results of the univariate analyses and Cox multivariate analyses of factors predicting the OS (n = 52)

From: The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study

 

Univariate

Multivariate

Variables

HR (95% CI)

p Value*

HR (95% CI)

p Value*

Age

 (< 70 years vs. ≥70 years)

2.307 (0.93–5.76)

0.073

  

Sex

 (Male vs. Female)

1.773 (1.20–2.61)

0.004

1.679 (1.13–2.50)

0.011

Prior nephrectomy

 (yes vs. no)

1.190 (0.41–3.46)

0.749

  

ECOG PS

 (0 vs. ≥1)

2.481 (1.14–5.38)

0.021

  

Treatment line of nivolumab

 (2 vs. ≥3)

1.371 (0.62–3.03)

0.434

  

IMDC risk classification

 (Favorable, Intermediate vs. Poor)

1.939 (0.73–5.16)

0.185

  

Number of Metastatic Organ site

 (1,2 vs. ≥3)

1.799 (0.83–3.89)

0.135

  

CRP at baseline

 (< 10 mg/L vs. ≥10 mg/L)

1.025 (0.47–2.23)

0.951

  

NLR at baseline

 (< 3 vs. ≥3)

1.011 (0.46–2.23)

0.979

  

NLR at 4 weeks

 (< 3 vs. ≥3)

2.857 (1.14–7.18)

0.026

2.734 (1.08–6.92)

0.034

  1. *Cox proportional hazards model
  2. OS Overall survival; HR Hazard ratio; CI confidence interval; ECOG Eastern Cooperative Oncology Group; PS Performance status; IMDC International Metastatic Renal Cell Carcinoma Database Consortium; CRP C-reactive protein; NLR Neutrophil-to-lymphocyte ratio